Hindustan Foods Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Record quarter, PAT guidance introduced: EBITDA hit ₹93 cr and PAT ₹36 cr, the highest ever, and the company gave its first FY27 PAT guidance of ₹200–₹220 cr, implying ~1.4x growth.
• ₹750 cr capex cycle is the core story: Over 60% of opening gross block was invested this year, with new capacities now commercializing; the full earnings reflection is pushed into FY27 and FY28.
• Duty inversion is reshaping revenue optics: GST cuts on bottled water, ice cream and foods created a mismatch with input rates, so the company is shifting customers to a conversion-based model that will optically lift margins but leave absolute profit unchanged.
• Export ambition is real but distant: A new international division has been set up and the shoe business is seen as the primary export driver, yet lead times of 6–8 months mean material results are still a story for the second half of CY26.
• What to watch next quarter: Whether the Mysuru ice cream capacity doubling ramps up on schedule through the April–July season, any closure on the Aurangabad M&A, and concrete progress on conversion-model customer negotiations.

The Capex Cycle: Commercialization Meets a Lag

• Capex intensity: Cumulative capex of over ₹750 cr in FY26 was funded through internal accruals, debt and preferential equity, with every project evaluated against an 18% ROCE threshold.
• Operational track record: All projects were completed on time with no cost overruns; 5 lakh+ sq ft built and high-speed machines installed across beverages, ice cream and home care.
• Commercialization timeline: Mysuru and Lucknow capacities are now commercialized and ramping from Q4; Nashik and Panipat are on track for season production; a brownfield detergent facility at Silvassa targets Q1 FY27 commercialization.
• The lag problem: The ₹750 cr capex will take time to reflect completely between FY27 and FY28, and new HPC segment capex will start reflecting only in FY28. Management did not directly answer an analyst's question about why FY27 profit guidance appears incommensurate with the gross block increase.
• ROCE disconnect explained: Reported ROCE is 14%–15% versus an internal 18% threshold because of capital work in progress and assets that are commercialized but not yet ramped up to normalized earning capacity.
• New disclosure on adjusted capital: Slide 13 of the presentation now shows a line for "to be commissioned and underutilized" assets, including CWIP, commercialized-but-not-ramped-up assets, and capital advances.
• Underutilization is structural, not operational: Management defines underutilization strictly as timing-driven (an asset coming on board post-season, like Panipat), not as a fault of execution or demand. A rough split of the ₹405 cr in this bucket is ~₹200 cr underutilized/ramping up, with the rest in CWIP and capital advances.

Kothari: "Underutilized for us would be very clearly structural underutilization. Structural underutilization would refer to the timing of the asset coming on board, let's say, an asset comes on board post the season, like I just talked about Panipat, in which case, it will continue to remain underutilized for a larger part of next year in spite of the fact that it's being commercialized."

GST Duty Inversion: An Optical Shift, Not a Profit One

• The mismatch: GST was cut on bottled water, ice cream and foods while input components stayed at the same rate, creating a gap between outgoing and incoming GST that increases working capital requirements.
• The fix: The company is discussing a transition to a conversion-based business model with certain customers, where the customer supplies raw material and the company bills only for conversion cost.
• Optical consequences: Reported revenue will fall and margins will appear higher, but absolute profitability remains unchanged. Management explicitly warned analysts not to misinterpret the coming margin improvement as real.
• Early stage: Discussions with customers have just begun; management declined to quantify the percentage of business affected or the revenue-side impact, calling it too early.
• Working capital approach at Panipat: For the new Panipat facility, discussions have already been initiated with the customer to bill only for conversion costs rather than buying raw material and packing material.

Kothari: "The profitability of the company will remain the same. However, the revenues will probably change and the recognition of revenues will change. In which case, frankly, the margins will appear very good, and some of you might actually pat us on our back saying that the margins have improved, though it will just be an optical improvement and the fact of the matter is we'll make the same amount of money that we were making earlier."

Ice Cream & Beverages: Geared for the Season

• Mysuru capacity doubled: Commercial production starts this week, in time for the season; the ramp-up runs February–March, with the asset fully sweated from April through July. The capacity increase was achieved without proportionate capex because existing land was used.
• Nashik and Panipat on track: Both facilities are on track to deliver production for the upcoming season commencing Q4 FY26.
• Panipat timing caveat: Expected commercialization is Q1 FY27, but the asset will ramp to full earning capacity only in FY28 due to seasonality: April–June is ramping up, with actual earnings starting in the CY28 season (Q4 FY27 and Q1 FY28).
• Dedicated model protects profitability: A large part of the ice cream business is dedicated, so profitability is not subject to the vagaries of the season; there could be timing differences across quarters, but at year-end the number is protected irrespective of a hot or cold summer.
• Backward integration moves: The company acquired a cone manufacturing facility and set up a stick manufacturing facility for the ice cream business, and has signed a couple of new ice cream customers.
• Beverages bullishness: Management is bullish about beverages and expects to expand capacity further in that segment; a new bottled water facility in the West is targeted for Q3 FY27 commercialization.

Exports & International: Ambition with a 6–8 Month Fuse

• International Business Division set up: Headed by an experienced executive; management expects to start seeing results in the next 6 months.
• Shoes as the export driver: The shoe business is expected to be the key driver of export business, with management "very, very optimistic" about trade agreements with the EU and US. The division has now stabilized and cost-saving initiatives are beginning to show results.
• OTC Pharma export slowdown: An export project with a US-based customer was going slow due to 6 months of tariff uncertainty; the team has recently been strengthened to go after export OTC business including Dr. Scholl-type products.
• Long lead times: Both shoes (fashion-driven) and OTC Pharma (regulatory requirements) carry 6–8 month lead times for exports, so material results are a second-half CY26 story.
• ROCE-accretive without fresh capex: The OTC export business is expected to be incremental and ROCE-accretive because additional business may not require additional capex.

Kothari: "I think this will be the sector which will be most benefited by the trade agreements, both with the EU as well as the U.S. We are definitely very, very optimistic that the shoe business will be the one who will drive our export business."

Capital Allocation & Balance Sheet: Conservative, Growth-Funded

• Debt philosophy: The company will not be overly adventurous with debt; it will stick to traditional project loans and avoid experimental instruments or foreign-exchange-denominated debt, even at the expense of a few basis points in the short run.
• Growth funded 1:1: Management stated that operating cash flows levered 1:1 with debt should support ~20% growth per year; if investment stops, the company will start returning money to shareholders via dividends.
• Finance cost discipline: Quarterly finance cost has not increased despite taking extra loans, because interest is a pass-through cost in the dedicated business.
• Capex journey continues: New capex announced in the HPC segment (₹50 cr greenfield project) will start reflecting only in FY28; the company continues to work on a pipeline of leads and announces capex only after contracts are signed.
• New M&A at Aurangabad: On track, expected to close in Q4 FY26.
• Baddi ayurvedic wellness products: Capex announced for manufacturing ayurvedic wellness products; production to start in the middle of next year.

Kothari: "We will not be overly adventurous with debt... just in the quest of trying to get an arbitrage, we will not get experimental with new instruments of debt or foreign exchange denominated debt, etcetera. I think we will continue to be conservative even if it is at the expense of certain bps in the short run."

Guidance & Commitments

Key Metrics